5,245 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by Bridgewater Associates LP

Bridgewater Associates LP bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 5,245 shares of the biotechnology company's stock, valued at approximately $638,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Louisiana State Employees Retirement System boosted its position in Sarepta Therapeutics by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock valued at $3,222,000 after purchasing an additional 100 shares during the last quarter. Manchester Capital Management LLC raised its stake in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after buying an additional 110 shares during the period. UMB Bank n.a. lifted its holdings in Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company's stock valued at $63,000 after purchasing an additional 138 shares during the last quarter. CIBC Asset Management Inc grew its stake in Sarepta Therapeutics by 5.1% in the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock valued at $347,000 after buying an additional 139 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Sarepta Therapeutics by 5.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after purchasing an additional 145 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on SRPT. Wells Fargo & Company began coverage on Sarepta Therapeutics in a research note on Friday, April 11th. They issued an "overweight" rating and a $115.00 price target for the company. Scotiabank decreased their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research note on Thursday, March 20th. Piper Sandler dropped their price objective on Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday. Morgan Stanley reduced their price objective on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research note on Friday, April 11th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $158.70.

Sarepta Therapeutics Trading Up 3.8 %

Shares of NASDAQ:SRPT traded up $2.27 during mid-day trading on Thursday, hitting $61.76. The company had a trading volume of 1,561,681 shares, compared to its average volume of 1,426,159. The company has a market capitalization of $5.99 billion, a PE ratio of 49.41 and a beta of 0.93. Sarepta Therapeutics, Inc. has a one year low of $48.01 and a one year high of $173.25. The firm has a fifty day moving average price of $79.14 and a 200 day moving average price of $106.58. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This trade represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.